Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the latest bullish announcement from the biotech.

Viking Therapeutics' positive results for oral weight-loss drug has analysts backing buy ratings

Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have emerged as dominant players, capturing significant market demand.

Missed out on Eli Lilly and Novo Nordisk? This pharma stock could be the next ‘big thing'

Viking Therapeutics (NASDAQ: VKTX ) stock is up on Tuesday as the company posts positive results from a short-term study of its weight loss drug. These results come from its Phase 1 study of VK2735.

Why Is Viking Therapeutics (VKTX) Stock Up 24% Today?

Viking Therapeutics Inc   (NASDAQ:VKTX) is skyrocketing today, last seen up 22.3% at $84.62.

Viking Therapeutics Stock Soars on Successful Trial

Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug beat expectations in a 28-day study.

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly — Beats Expectations In Just 28 Days

Viking Therapeutics is developing a weight loss drug that looks great. It also just raised a boat load of money with a stock offering.

Viking Therapeutics: Buy, Sell, or Hold?

Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics' oral weight-loss drug effective?

Viking Therapeutics stock ($VKTX) pops 20% on oral weight-loss drug trial data

The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.

Viking Therapeutics stock jumps 15% on promising weight loss pill data

Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.

Viking Therapeutics says its experimental tablet reduced weight in early-stage study

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity.

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Eli Lilly

Novo Nordisk

Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the way.

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

Iovance Biotherapeutics

The Nasdaq Composite index is up sharply over the past year, but it contains at least two growth stocks poised to run even higher. Investment bank analysts who follow Viking Therapeutics think the stock can gain another 47% following a big run-up.

2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street

Apple

AerCap Hlds

Amazon

Boeing

Black Diamond Therapeutics

Dream Finders Homes

D.R. Horton

Airbus SE

General Electric

Alphabet

Green Brick Partners

Howmet Aerospace

Hexcel

KB Home

Microsoft

Tesla

United Continental Hlds

The rate of rise for big-cap tech stocks is slowing down or losing altitude, suggesting it may not be the best time to invest in them. The economy is growing, inflation is under control, and the Fed is committed to cutting rates, creating opportunities in other sectors. Areas such as housing, biotech and MedTech stocks, and the aviation industry may offer better investment opportunities.

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

Viking Therapeutics stock has been soaring this year due to optimism about its weight loss drug candidate. The stock is a risky buy, however, as the company isn't profitable or generating any consistent revenue.

Is Viking Therapeutics Stock a Millionaire Maker?

Three very different potential scenarios for Viking Therapeutics' future seem possible. Only one of these potential scenarios is negative for Viking's shareholders.

Where Will Viking Therapeutics Stock Be in 10 Years?

Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works in the same way as the Lilly drugs.

Could Viking Therapeutics Become the Next Eli Lilly?

The biotech is getting a lot of attention for one of its pipeline drugs. VK2735 looks like it has a solid chance at becoming a blockbuster obesity treatment.

Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street Analyst

Cytokinetics

Smaller drug developers have struggled in the current high-interest-rate environment. With the central bank poised to pivot on rates later this year, these stocks could be gearing up for a trend reversal.

2 Incredible Growth Stocks to Buy Right Now

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.

Time to be "Overweight" Viking Therapeutics

Viking Therapeutics has a GLP-1 drug that could be a big player in the anti-obesity market. For big pharma, the stock could make for an attractive acquisition target.

Will Viking Therapeutics Get Acquired?

Janux Therapeutics

Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.

2 Stocks That Have More Than Tripled This Year: Are They Buys?

Pfizer

Pfizer's pipeline already includes two obesity drugs. However, doubts about Pfizer's lead obesity program could make buying Viking a smart move.

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Arrowhead Pharmaceuticals

CRISPR Therapeutics

Halozyme Therapeutics

Jazz Pharmaceuticals

SpringWorks Therapeutics Inc

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

Broadcom

Palantir Technologies

With the stock market trading around record highs, we have compiled three top stocks for long-term investors. Despite concerns regarding potential macroeconomic headwinds and global geopolitical instability, the bullish market sentiment continues on Wall Street.

Unleashing the Bulls: 3 Top Stocks to Charge Ahead in March

Viking is working on a weight-loss drug candidate that works in the same way as Eli Lilly's top-selling drug. The company released positive data recently, and the shares soared in the triple digits.

News for Viking Therapeutics Stock (VKTX)